RA
Rapport Therapeutics, Inc. Common Stock
RAPP · NASDAQ
$40.45 -5.93% (-$2.55)
1M -18.00%
Market Cap $2.01B
P/E Ratio -
Div. Yield -
ROE 29.02%
Piotroski F-Score Weak
2/9Valuation
21 /100
Expensive P/B 4.74x
P/S 100.32x
EV/FFO N/A
Growth
100 /100
Growing Book val. growth 191.81%
FCF growth N/A
EPS growth N/A
Profitability
20 /100
Weak Op. margin 767.58%
Gross margin 100.00%
FCF margin 485.75%
Quality
1 /100
Poor ROA 29.88%
ROIC 35.45%
Asset turnover 0.04x
Debt
100 /100
Low Current ratio 15.72x
Debt/Equity 0.02x
Debt/Assets N/A
Stability
31 /100
Unstable Profitable years 0
Beta 1.03x
EPS volatility 169.43%
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na RAPP
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Abraham N. Ceesay
Employees
84
Headquarters
Boston
Nadcházející události
05 LIS
Earnings
Upcoming earnings report